# CAMP4 Therapeutics

> Regulatory RNA-targeting therapeutics to upregulate gene expression.

## Why it is interesting

CAMP4 maps regRNA biology to restore healthy protein levels — a16z led the Series A before the company went public on Nasdaq (CAMP).

## Profile

- **Stage:** public
- **Status:** public
- **Industries:** biotech, healthcare
- **Coverage:** full
- **Last updated:** 2026-07-24

## Key facts

- Public (Nasdaq: CAMP): private placement and public listing activity in 2025 (CAMP4 IR)
- Series A (2018): $30M led by a16z; Polaris, Kraft Group participated (GenomeWeb)
- Series B (2022): $100M led by Enavate Sciences; a16z re-upped (BusinessWire)
- Co-investors: no additional institutional investors disclosed in public sources reviewed 2026-07-24
- Source: https://www.genomeweb.com/business-news/computational-biology-startup-camp4-therapeutics-launches-30m-series-funding

## Investors in our directory

- https://venturecapitaltracker.com/fund/andreessen-horowitz

## Related articles

- https://venturecapitaltracker.com/2026-a16z-hot-portfolio-companies

---
Source: https://venturecapitaltracker.com/startup/camp4-therapeutics